HC Wainwright Issues Negative Outlook for Nkarta Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Stock analysts at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of Nkarta in a report issued on Thursday, March 26th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.40) for the quarter, down from their prior forecast of ($0.34). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($1.66) EPS, FY2029 earnings at ($1.49) EPS and FY2030 earnings at ($1.13) EPS.

Several other analysts also recently commented on NKTX. Needham & Company LLC increased their price objective on shares of Nkarta from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a report on Friday. Wall Street Zen cut shares of Nkarta from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Mizuho reduced their price target on shares of Nkarta from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $11.33.

Nkarta Price Performance

Shares of NASDAQ:NKTX opened at $2.11 on Monday. The business has a fifty day moving average price of $2.28 and a 200-day moving average price of $2.10. The company has a market capitalization of $156.75 million, a PE ratio of -1.51 and a beta of 0.47. Nkarta has a 1-year low of $1.42 and a 1-year high of $2.81.

Nkarta (NASDAQ:NKTX) last released its earnings results on Wednesday, March 25th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05).

Institutional Trading of Nkarta

Institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC raised its holdings in shares of Nkarta by 70.0% during the fourth quarter. Hsbc Holdings PLC now owns 161,434 shares of the company’s stock valued at $299,000 after purchasing an additional 66,479 shares during the last quarter. Invesco Ltd. boosted its holdings in Nkarta by 28.8% in the fourth quarter. Invesco Ltd. now owns 150,476 shares of the company’s stock worth $278,000 after purchasing an additional 33,632 shares during the last quarter. XTX Topco Ltd boosted its holdings in Nkarta by 698.4% in the fourth quarter. XTX Topco Ltd now owns 134,730 shares of the company’s stock worth $249,000 after purchasing an additional 117,856 shares during the last quarter. Man Group plc grew its position in Nkarta by 102.7% in the 4th quarter. Man Group plc now owns 88,438 shares of the company’s stock worth $164,000 after purchasing an additional 44,810 shares during the period. Finally, Bridgeway Capital Management LLC raised its stake in Nkarta by 22.8% during the 4th quarter. Bridgeway Capital Management LLC now owns 107,800 shares of the company’s stock valued at $199,000 after buying an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 26,046 shares of Nkarta stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $2.07, for a total value of $53,915.22. Following the completion of the sale, the chief executive officer directly owned 390,023 shares in the company, valued at approximately $807,347.61. This trade represents a 6.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.40% of the company’s stock.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.